Annual EBITDA
-$152.18 M
-$48.17 M-46.32%
31 December 2023
Summary:
Keros Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$152.18 million, with the most recent change of -$48.17 million (-46.32%) on 31 December 2023. During the last 3 years, it has fallen by -$106.93 million (-236.31%). KROS annual EBITDA is now -12928.85% below its all-time high of -$1.17 million, reached on 31 December 2018.KROS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$58.34 M
-$8.21 M-16.38%
30 September 2024
Summary:
Keros Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$58.34 million, with the most recent change of -$8.21 million (-16.38%) on 30 September 2024. Over the past year, it has dropped by -$15.27 million (-35.46%). KROS quarterly EBITDA is now -2523.34% below its all-time high of -$2.22 million, reached on 30 June 2019.KROS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$185.94 M
-$15.27 M-8.95%
30 September 2024
Summary:
Keros Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$185.94 million, with the most recent change of -$15.27 million (-8.95%) on 30 September 2024. Over the past year, it has dropped by -$33.43 million (-21.92%). KROS TTM EBITDA is now -6961.94% below its all-time high of -$2.63 million, reached on 31 March 2019.KROS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KROS EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -46.3% | -35.5% | -21.9% |
| 3 y3 years | -236.3% | -188.4% | -199.3% |
| 5 y5 years | -10000.0% | -1571.2% | -2127.4% |
KROS EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -236.3% | at low | -1106.4% | at low | -230.0% | at low |
| 5 y | 5 years | <-9999.0% | at low | -2068.1% | at low | -2127.4% | at low |
| alltime | all time | <-9999.0% | at low | -2523.3% | at low | -6961.9% | at low |
Keros Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$58.34 M(+16.4%) | -$185.94 M(+8.9%) |
| June 2024 | - | -$50.13 M(+4.0%) | -$170.67 M(+5.6%) |
| Mar 2024 | - | -$48.21 M(+64.8%) | -$161.68 M(+6.2%) |
| Dec 2023 | -$152.18 M(+46.3%) | -$29.26 M(-32.1%) | -$152.18 M(-0.2%) |
| Sept 2023 | - | -$43.07 M(+4.7%) | -$152.51 M(+14.8%) |
| June 2023 | - | -$41.15 M(+6.3%) | -$132.82 M(+12.0%) |
| Mar 2023 | - | -$38.70 M(+30.8%) | -$118.63 M(+14.1%) |
| Dec 2022 | -$104.00 M(+84.6%) | -$29.59 M(+26.5%) | -$104.00 M(+31.2%) |
| Sept 2022 | - | -$23.38 M(-13.3%) | -$79.25 M(+4.1%) |
| June 2022 | - | -$26.96 M(+12.0%) | -$76.10 M(+17.7%) |
| Mar 2022 | - | -$24.07 M(+397.8%) | -$64.67 M(+14.8%) |
| Dec 2021 | -$56.35 M | -$4.84 M(-76.1%) | -$56.35 M(-9.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$20.23 M(+30.3%) | -$62.12 M(+15.4%) |
| June 2021 | - | -$15.53 M(-1.4%) | -$53.85 M(+9.9%) |
| Mar 2021 | - | -$15.75 M(+48.6%) | -$49.00 M(+8.3%) |
| Dec 2020 | -$45.25 M(+273.3%) | -$10.60 M(-11.4%) | -$45.25 M(+21.2%) |
| Sept 2020 | - | -$11.96 M(+11.9%) | -$37.34 M(+29.3%) |
| June 2020 | - | -$10.69 M(-10.9%) | -$28.87 M(+41.5%) |
| Mar 2020 | - | -$12.00 M(+345.9%) | -$20.41 M(+84.8%) |
| Dec 2019 | -$12.12 M(+937.7%) | -$2.69 M(-22.9%) | -$11.04 M(+32.2%) |
| Sept 2019 | - | -$3.49 M(+57.0%) | -$8.35 M(+71.9%) |
| June 2019 | - | -$2.22 M(-15.5%) | -$4.86 M(+84.5%) |
| Mar 2019 | - | -$2.63 M | -$2.63 M |
| Dec 2018 | -$1.17 M | - | - |
FAQ
- What is Keros Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Keros Therapeutics?
- What is Keros Therapeutics annual EBITDA year-on-year change?
- What is Keros Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Keros Therapeutics?
- What is Keros Therapeutics quarterly EBITDA year-on-year change?
- What is Keros Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Keros Therapeutics?
- What is Keros Therapeutics TTM EBITDA year-on-year change?
What is Keros Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of KROS is -$152.18 M
What is the all time high annual EBITDA for Keros Therapeutics?
Keros Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$1.17 M
What is Keros Therapeutics annual EBITDA year-on-year change?
Over the past year, KROS annual earnings before interest, taxes, depreciation & amortization has changed by -$48.17 M (-46.32%)
What is Keros Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of KROS is -$58.34 M
What is the all time high quarterly EBITDA for Keros Therapeutics?
Keros Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$2.22 M
What is Keros Therapeutics quarterly EBITDA year-on-year change?
Over the past year, KROS quarterly earnings before interest, taxes, depreciation & amortization has changed by -$15.27 M (-35.46%)
What is Keros Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of KROS is -$185.94 M
What is the all time high TTM EBITDA for Keros Therapeutics?
Keros Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.63 M
What is Keros Therapeutics TTM EBITDA year-on-year change?
Over the past year, KROS TTM earnings before interest, taxes, depreciation & amortization has changed by -$33.43 M (-21.92%)